UChicago Medicine 21st Annual International Ultmann Chicago Lymphoma Symposium 2024

Name: UChicago Medicine 21st Annual International Ultmann Chicago Lymphoma Symposium 2024 - DrMedciene
SKU: MED-AMB-00946
Price: 40.00 USD
Availability: InStock

$40.00

This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!

Include: 26 videos + 1 pdf, size: 7.52 GB

SKU: MED-AMB-00946 Categories: Hematology / Oncology, Internal Medicine, Pathology courses Tags: Internal Medicine, Oncology, Pathology

Description

UChicago Medicine 21st Annual International Ultmann Chicago Lymphoma Symposium 2024

Include: 26 videos + 1 pdf, size: 7.52 GB

Target Audience: oncologists

Information:

The 21st International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.

We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of national practicing oncologists, advanced nurse practitioners and physician assistants, nurses, residents, fellows, and the Chicago academic community that includes five academic centers. This year’s program will be offered live on April 19-20, 2024, and represents the 21st IUCLS.

UChicago Medicine 21st Annual International Ultmann Chicago Lymphoma Symposium 2024

This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. The format of the meeting includes a combination of expert presentations, interactive case discussions, poster and abstract presentations, and an opportunity for question-and-answer debates. Additionally, the entire conference will be certified for nursing continuing education credits.

The goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.

IUCLS will gather both domestic and international clinicians and researchers specializing in the treatment of patients with lymphoma.This event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.

Target Audience

This activity is designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and other healthcare professionals interested in the treatment and diagnosis of lymphoma.

Learning Objectives

At the conclusion of this educational activity, participants will be able to:

Evaluate the latest treatment strategies for patients with indolent and aggressive forms of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma;
Assess the safety and efficacy of current and emerging therapeutic approaches for the care of patients with Hodgkin lymphoma;
Compare and contrast the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL;
Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma;
Develop strategies to communicate with and utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.

Topics:

2024 IUCLS Agenda FINAL.pdf
Are Checkpoint Inhibitors the Standard of Care for Frontline Hodgkin Lymphoma.mp4
Artificial Intelligence and Computational Oncology.mp4
Bispecifics for FL.mp4
Bispecifics for LBCL Focus on Management of Toxicities in the Community.mp4
Duel Symposium Measuring MRD is the Standard of Care in CLL No.mp4
Duel Symposium Measuring MRD is the Standard of Care in CLL Yes.mp4
Ensuring the Progress in Hodgkin Lymphoma Applies to All.mp4
Epigenetics in T-cell Lymphoma Has the Promise Been Fulfilled.mp4
Hematopathology Tumor Board.mp4
Implementation of Reducing Barriers to Accessing Lymphoma Care.mp4
Keynote Presentation The Evolution and State of Lymphoma Research.mp4
Management of Advanced CTCL.mp4
Novel Therapeutics for T-cell Lymphoma and Lessons Learned from the Current Regulatory Environment.mp4
Overview of Bispecific Antibodies- Comparing and Contrasting Current and Emerging Agents.mp4
Panel Discussion with Cases Hodgkin’s Lymphoma.mp4
PI3K Is Targeting This Pathway Still Valuable.mp4
Practical Aspects of Bispecifics Supportive Care Strategies.mp4
Primer on CRISPR and its Impact on Cancer Research and Treatment.mp4
Sequencing of Bispecifics with Other Therapies.mp4
Special Considerations in Treating Patients with Lymphoma – Impact of Patient Age AYA Patients.mp4
Special Considerations in Treating Patients with Lymphoma – Impact of Patient Age Elderly Older Patients.mp4
Supportive Care for Patients with HL Receiving Immunotherapy- Differentiating Checkpoint Inhibitors vs Antibody-Drug Conjugates.mp4
Targeting BTK- Inhibitors vs Degraders.mp4
The Next Frontier of Targeted Therapy in Lymphoma.mp4
What is the Standard of Care in Second Line Hodgkin Lymphoma.mp4
Who Benefits the Most from Radiation in Hodgkin Lymphoma.mp4